Paul Kwo

4.9/5

Biography

Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He has distinguished himself in the field of Hepatitis C therapeutics and has been the principal investigator on multiple international trials. He recently authored the ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

View Full Biography

Professional Summary

Education & Certifications

Residency: University of Maryland Medical Center (1991) MD
Board Certification: American Board of Internal Medicine, Transplant Hepatology (2006)
Board Certification: American Board of Internal Medicine, Gastroenterology (1995)
- Fellowship: Mayo Clinic Graduate Medical Education (1995) MN
- Medical Education: Wayne State University School of Medicine (1988) MI

View More Education & Certifications

Honors & Awards

America's Best Doctors: Gastroenterology/Hepatology, Best Doctors in America (2003-2015)
America’s Top Doctors Gastroenterology/Hepatology, Consumers Research Council of America (2002-2014)
America’s Top Doctors, Gastroenterology/Hepatology, Castle Connelly Publishing, (2002-2016, 2018-2020)
- Best Doctors Gastroenterology/Hepatology, Best Doctors in America (2003-2015)
- Outstanding Young Clinician, Department of Medicine, Indiana University School of Medicine (2003)

View More Honors & Awards

Memberships

Development Committee, American Association for the Study of Liver Diseases (2015 - Present)
Editorial Board, Journal of Clinical Gastroenterology (2013 - Present)
Nominating Committee, American Association for the Study of Liver Disease (2016 - Present)
- Board of Trustees, American College of Gastroenterology (2015 - Present)

View More Memberships

Administrative Appointments

Director of Hepatology, Stanford University (2016 - Present)
Liver Clinic Chief, Digestive Health (2018 - Present)

Publications

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N, A. (2014). Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. . N Engl J Med, 370(16).
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.
Gane, E., Kowdley, K. V., Pound, D., Stedman, C. A. M., Davis, M., Etzkorn, K., … Nguyen, M. H. (2016). Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gastroenterology.
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Kwo, P., Gane, E. J., Peng, C.-Y., Pearlman, B., Vierling, J. M., Serfaty, L., … Haber, B. (2017). Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. GASTROENTEROLOGY, 152(1), 164-?
- International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.
  Terrault, N., Berenguer, M., Strasser, S., gadano, adrian, Lilly, L., Samuel, D., … McCaughan, G. W. (2017). International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS. Transplantation.
- International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.
  Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J., … Berenguer, M. (2017). International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES. Transplantation.
- Confirming What We Believed: Reducing and Eliminating Vertical Transmission of Hepatitis B.
  Kligman, E., & Kwo, P. Y. (2017). Confirming What We Believed: Reducing and Eliminating Vertical Transmission of Hepatitis B. Gastroenterology.
- Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
  Kwo, P., Gane, E. J., Peng, C.-Y., Pearlman, B., Vierling, J. M., Serfaty, L., … Haber, B. (2017). Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology, 152(1), 164–75 e4.
- ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
  Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 112(1), 18–35.
- ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
  Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112(1), 17–36.
- International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates
  Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J. Y. Y., … Berenguer, M. (2017). International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. TRANSPLANTATION, 101(5), 945–55.
- International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients
  Terrault, N. A., Berenguer, M., Strasser, S. I., gadano, adrian, Lilly, L., Samuel, D., … McCaughan, G. W. (2017). International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. TRANSPLANTATION, 101(5), 956–67.
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
  Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., … Mensa, F. J. (2017). Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. Journal of Hepatology.
- Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded
  Liangpunsakul, S., & Kwo, P. Y. (2017). Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 15(2), 289–91.
- All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database
  Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., … Manns, M. P. (2017). All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 45(1), 115–26.
- After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver
  Kwo, P. Y., & Lacerda, M. A. (2016). After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver. GASTROENTEROLOGY, 151(4), 582–84.
- High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
  Gane, E., Poordad, F., Wang, S., Asatryan, A., Kwo, P. Y., Lalezari, J., … Mensa, F. J. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. GASTROENTEROLOGY, 151(4), 651-?
- Hepatic arterial buffer response: pathologic evidence in non-cirrhotic human liver with extrahepatic portal vein thrombosis
  Rush, N., Sun, H., Nakanishi, Y., Mneimneh, W., Kwo, P. Y., & Saxena, R. (2016). Hepatic arterial buffer response: pathologic evidence in non-cirrhotic human liver with extrahepatic portal vein thrombosis. MODERN PATHOLOGY, 29(5), 489–99.
- Risk factors for bleeding after liver biopsy
  Sandrasegaran, K., Thayalan, N., Thavanesan, R., Kohli, M., Berry, W., Shah, A., & Kwo, P. (2016). Risk factors for bleeding after liver biopsy. ABDOMINAL RADIOLOGY, 41(4), 643–49.
- Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study
  Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Etzkorn, K., Rojter, S., … Witek, J. (2016). Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. HEPATOLOGY, 64(2), 370–80.
- Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
  Chan, H. L. Y., Ahn, S. H., Chang, T.-T., Peng, C.-Y., Wong, D., Coffin, C. S., … Cooney, E. (2016). Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). JOURNAL OF HEPATOLOGY, 64(5), 1011–19.
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
  Curry, M. P., O'Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., … Charlton, M. (2015). Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. NEW ENGLAND JOURNAL OF MEDICINE, 373(27), 2618–28.
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
  Alqahtani, S. A., Afdhal, N., Zeuzem, S., Gordon, S. C., Mangia, A., Kwo, P., … Sulkowski, M. (2015). Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. HEPATOLOGY, 62(1), 25–30.
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
  Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., … Afdhal, N. (2015). Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. GASTROENTEROLOGY, 149(3), 649–59.
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
  Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Braeu, N., … Yin, P. D. (2015). Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 313(17), 1728–35.
- Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial
  Rex, D. K., Clodfelter, R., Rahmani, F., Fatima, H., James-Stevenson, T. N., Tang, J. C., … Kwo, P. Y. (2016). Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial. GASTROINTESTINAL ENDOSCOPY, 83(1), 166–71.
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
  Muir, A. J., Poordad, F., Lalezari, J., Everson, G., Dore, G. J., Herring, R., … Yin, P. D. (2015). Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 313(17), 1736–44.
- Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.
  Lasley, F. D., Mannina, E. M., Johnson, C. S., Perkins, S. M., Althouse, S., Maluccio, M., … Cárdenes, H. (2015). Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical Radiation Oncology, 5(5), e443–9.
- The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma
  Umar, N. K., Badshah, M. B., Sandrasegaran, K., Ghabril, M., Agarwal, S., Tann, M., … Kwo, P. Y. (2015). The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma. DIGESTIVE DISEASES AND SCIENCES, 60(7), 2196–2200.
- Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity
  Burman, B. E., Kwo, P. Y., & Kowdley, K. V. (2014). Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. HEPATOLOGY INTERNATIONAL, 8(3), 352–64.
- An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
  Kwo, P. Y., Mantry, P. S., Coakley, E., Te, H. S., Vargas, H. E., Brown, R., … Forns, X. (2014). An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 371(25), 2375–82.
- The future of hepatitis C virus therapeutics.
  Kwo, P. Y. (2014). The future of hepatitis C virus therapeutics. Gastroenterology & Hepatology, 10(7), 433–35.
- Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
  Vierling, J. M., Zeuzem, S., Poordad, F., Bronowicki, J.-P., Manns, M. P., Bacon, B. R., … Bruno, S. (2014). Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. JOURNAL OF HEPATOLOGY, 61(2), 200–209.
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
  Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., … Marcellin, P. (2014). Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. NEW ENGLAND JOURNAL OF MEDICINE, 370(20), 1889–98.
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
  Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., … Fried, M. W. (2014). Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. NEW ENGLAND JOURNAL OF MEDICINE, 370(20), 1879–88.
- Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant
  Kwo, P. Y., Ghabril, M., Lacerda, M. A., Tector, A. J., Fridell, J. A., & Vianna, R. (2014). Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. CLINICAL TRANSPLANTATION, 28(6), 722–27.
- Role of Cardiac Catheterization and Percutaneous Coronary Intervention in the Preoperative Assessment and Management of Patients Before Orthotopic Liver Transplantation
  Maddur, H., Bourdillon, P. D., Liangpunsakul, S., Tector, A. J., Fridell, J. A., Ghabril, M., … Kwo, P. Y. (2014). Role of Cardiac Catheterization and Percutaneous Coronary Intervention in the Preoperative Assessment and Management of Patients Before Orthotopic Liver Transplantation. LIVER TRANSPLANTATION, 20(6), 664–72.
- Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
  Manns, M. P., McCone, J., Davis, M. N., Rossaro, L., Schiff, E., Shiffman, M. L., … Vierling, J. M. (2014). Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. LIVER INTERNATIONAL, 34(5), 707–19.
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
  Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., … Bernstein, B. (2014). Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. NEW ENGLAND JOURNAL OF MEDICINE, 370(3), 222–32.
- Ethical Considerations Surrounding Survival Benefit-Based Liver Allocation
  Keller, E. J., Kwo, P. Y., & Helft, P. R. (2014). Ethical Considerations Surrounding Survival Benefit-Based Liver Allocation. LIVER TRANSPLANTATION, 20(2), 140–46.
- De novo malignancy post-liver transplantation: a single center, population controlled study
  Chatrath, H., Berman, K., Vuppalanchi, R., Slaven, J., Kwo, P., Tector, A. J., … Ghabril, M. (2013). De novo malignancy post-liver transplantation: a single center, population controlled study. CLINICAL TRANSPLANTATION, 27(4), 582–90.
- Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis
  Kwo, P. Y., & Tector, A. J. (2013). Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis. LIVER TRANSPLANTATION, 19(7), 780–81.
- Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
  Lawitz, E., Sulkowski, M., Jacobson, I., Kraft, W. K., Maliakkal, B., Al-Ibrahim, M., … Mobashery, N. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. ANTIVIRAL RESEARCH, 99(3), 214–20.
- The Liver in Oncology.
  Dhanasekaran, R., & Kwo, P. Y. (2017). The Liver in Oncology. Clinics in Liver Disease, 21(4), 697–707.
- Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.
  Cholankeril, G., Gonzalez, H. C., Satapathy, S., Gonzalez, S. A., Hu, M., Khan, M. A., … Ahmed, A. (2018). Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.
- Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States
  Rahim, U., Cholankeril, G., Yoo, E. R., Liu, A., Li, A. A., Kim, D., … Goel, A. (2017). Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States. HEPATOLOGY. WILEY.
- SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS
  Gane, E. J., Nguyen, M., Kwo, P., Kowdley, K., Reau, N., Jacobson, I., … Lawitz, E. (2016). SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation.
  Kwong, A., Wall, A., Melcher, M., Wang, U., Ahmed, A., Khush, K., … Kwo, P. (2018). Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.
- Pragmatic Surgical Risk Assessment Criteria in Critically Ill Patients Prior to Liver Transplantation.
  Bonham, C., Tulu, Z., Melcher, M., Kwo, P., Concepcion, W., Ahmed, A., & Esquivel, C. (2018). Pragmatic Surgical Risk Assessment Criteria in Critically Ill Patients Prior to Liver Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.
- Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis
  Flamm, S. L., Wyles, D. L., Wang, S., Mutimer, D. J., Rockstroh, J. K., Horsmans, Y. J., … Mensa, F. J. (2017). Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis. HEPATOLOGY. WILEY.
- Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
  Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., … Mensa, F. J. (2018). Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. NEW ENGLAND JOURNAL OF MEDICINE, 378(4), 354–69.
- Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
  Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., … Mensa, F. J. (2018). Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. HEPATOLOGY, 67(2), 514–23.
- The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment
  Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., & Maddrey, W. C. (2017). The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment. DRUG SAFETY, 40(12), 1205–18.
- A Prognostic Model for Liver Transplant Candidates with Hepatitis C - A Decision Aid for Antiviral Therapy
  Lee, H. W., Mannalithara, A., Asrani, S. K., Biggins, S. W., Heimbach, J., Brandman, D., … Kim, W. R. (2017). A Prognostic Model for Liver Transplant Candidates with Hepatitis C - A Decision Aid for Antiviral Therapy. HEPATOLOGY, 66, 548A–549A.
- Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts
  Wilson, E., Davitkov, P., Kwo, P. Y., Kattakuzhy, S., Qureshi, K., Sundaram, V., … Kowdley, K. V. (2017). Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts. HEPATOLOGY, 66, 608A.
- The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong
  Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. AMERICAN JOURNAL OF GASTROENTEROLOGY, 113(1), 2–4.
- Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy
  Dore, G., Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., … Haber, B. (2018). Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy. JOURNAL OF VIRAL HEPATITIS. WILEY.
- Response to Perrella et al.
  Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). Response to Perrella et al. The American Journal of Gastroenterology.
- Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C
  Kwo, P., Zhang, Z., Knapp, K., Hui, S. L., Kelley, A., Muschi, D., & Puenpatom, A. (2017). Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S502.
- Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment.
  Charville, G. W., Padda, S. K., Sibley, R. K., Puthillath, A., & Kwo, P. Y. (2018). Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment. Case Reports in Hepatology, 2018, 3413592.
- Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
  Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., … Forns, X. (2018). Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. HEPATOLOGY, 68(4), 1298–1307.
- Treatment of Hepatitis B in the Us; Real-World Evidence from the Trio Network
  Bae, H., Curry, M. P., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2018). Treatment of Hepatitis B in the Us; Real-World Evidence from the Trio Network. HEPATOLOGY, 68, 264A–265A.
- Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real-World Evidence from the Trio Network
  Curry, M. P., Bae, H., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2018). Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real-World Evidence from the Trio Network. HEPATOLOGY, 68, 252A.
- Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors.
  Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., & Kwo, P. Y. (2018). Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
- PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH
  Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P. J., Aguilar, R., … Harrison, S. A. (2018). PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH. SWISS MEDICAL WEEKLY. E M H SWISS MEDICAL PUBLISHERS LTD.
- High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals
  Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., … Gane, E. (2016). High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP.
- HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS
  Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., … Gane, E. J. (2016). HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Diagnosis and Management of Primary Biliary Cholangitis.
  Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2018). Diagnosis and Management of Primary Biliary Cholangitis. The American Journal of Gastroenterology.
- Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
  Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., … Wyles, D. L. (2018). Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis. Journal of Viral Hepatitis.
- Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort
  Kwo, P., Fried, M. W., Reddy, K. R., Soldevila-Pico, C., Khemichian, S., Darling, J., … Brown, R. S. (2018). Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort. HEPATOLOGY COMMUNICATIONS, 2(4), 354–63.
- The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.
  Wong, K., Ozeki, K., Kwong, A., Patel, B. N., & Kwo, P. (2018). The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PloS One, 13(12), e0208233.
- Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
  Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., … Kumada, H. (2019). Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. Journal of Gastroenterology.
- Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy
  Hezode, C., Kwo, P., Sperl, J., Dore, G., Hwang, P., Long, J., … Haber, B. (2018). Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis
  Poordad, F., Zeuzem, S., Asatryan, A., Foster, G., Gane, E., Wyles, D., … Mensa, F. (2018). Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Drug-drug interactions in hepatitis C virus treatment: Do they really matter?
  Ahmed, A., Lutchman, G. A., & Kwo, P. Y. (2017). Drug-drug interactions in hepatitis C virus treatment: Do they really matter? Clinical Liver Disease, 10(5), 111–15.
- Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
  Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., … Mensa, F. J. (2017). Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology (Baltimore, Md.).
- Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies
  Yao, B., Asselah, T., Fredrick, L., Schnell, G., Kowdley, K. V., Kwo, P., … Mensa, F. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
  Ma, X., Lalezari, J., Tuan Nguyen, Bae, H., Schiff, E. R., Fung, S., … Lopatin, U. (2019). Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice
  Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., … Afdhal, N. (2019). Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice. JOURNAL OF HEPATOLOGY, 70, E462.
- A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
  Lawitz, E., Gane, E., Ruane, P., Herring, J. R., Younes, Z. H., Kwo, P., … Loomba, R. (2019). A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Diagnosis and Management of Primary Biliary Cholangitis
  Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019). Diagnosis and Management of Primary Biliary Cholangitis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 114(1), 48–63.
- Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
  Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., … Wyles, D. L. (2019). Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. JOURNAL OF VIRAL HEPATITIS, 26(3), 337–49.
- Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014.
  Kim, D., Cholankeril, G., Li, A. A., Kim, W., Tighe, S. P., Hameed, B., … Ahmed, A. (2019). Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014. Liver International : Official Journal of the International Association for the Study of the Liver.
- The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer
  Wong, K., Ozeki, K., Kwong, A., Patel, B. N., & Kwo, P. (2018). The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PLOS ONE, 13(12).
- Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors
  Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., & Kwo, P. Y. (2019). Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. AMERICAN JOURNAL OF TRANSPLANTATION, 19(5), 1380–87.
- EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: AN INTEGRATED ANALYSIS OF PHASE 2 AND 3 STUDIES
  Yao, B. B., Asselah, T., Frederick, L., Schnell, G., Kowdley, K., Kwo, P. Y., … Lee, S. S. (2019). EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: AN INTEGRATED ANALYSIS OF PHASE 2 AND 3 STUDIES. GUT. BMJ PUBLISHING GROUP.
- Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
  Sripongpun, P., Mannalithara, A., Kwo, P. Y., & Kim, W. R. (2019). Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.
- Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance.
  Bonham, A., Tulu, Z., Concepcion, W., Gallo, A., Melcher, M., Kwo, P., … Esquivel, C. (2019). Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.
- CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US
  Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., … Afdhal, N. (2019). CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US. VALUE IN HEALTH. ELSEVIER SCIENCE INC.
- y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
  Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., … Kumada, H. (2019). y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. JOURNAL OF GASTROENTEROLOGY, 54(8), 752–61.
- Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease.
  Adejumo, A. C., Kim, D., Iqbal, U., Yoo, E. R., Boursiquot, B. C., Cholankeril, G., … Ahmed, A. (2019). Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. Journal of Palliative Medicine.
- Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
  Kwo, P. Y., Puenpatom, A., Zhang, Z., Hui, S. L., Kelley, A. A., & Muschi, D. (2019). Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PloS One, 14(8), e0218759.
- iLFT: A big assist in the recognition of liver disease in general practice.
  Cheung, A. C., & Kwo, P. Y. (2019). iLFT: A big assist in the recognition of liver disease in general practice. Journal of Hepatology.
- DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist Response
  Kwo, P. Y., Shiffman, M. L., & Bernstein, D. E. (2018). DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist Response. AMERICAN JOURNAL OF GASTROENTEROLOGY, 113(8), 1251–52.
- Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis
  Cholankeril, G., Gonzalez, H. C., Satapathy, S. K., Gonzalez, S. A., Hu, M., Khan, M. A., … Ahmed, A. (2018). Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 16(6), 965-+.
- Toward Elimination of Hepatitis C Infection: How Bestto Address Gaps in the Cascade of Care?
  Prabhakar, V., & Kwo, P. Y. (2019). Toward Elimination of Hepatitis C Infection: How Bestto Address Gaps in the Cascade of Care? Hepatology Communications, 3(9), 1174–76.
- Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014
  Kim, D., Cholankeril, G., Li, A. A., Kim, W., Tighe, S. P., Hameed, B., … Ahmed, A. (2019). Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. LIVER INTERNATIONAL, 39(9), 1661–71.
- CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC)
  Arjunan, V., Prabhakar, V., Raghavan, S. S., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2019). CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC). HEPATOLOGY, 70, 548A.
- IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)?
  Arjunan, V., Prabhakar, V., Raghavan, S. S., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2019). IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)? HEPATOLOGY, 70, 557A–558A.
- THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)
  Prabhakar, V., Dhanasekaran, R., Arjunan, V., Tulu, Z., Ahmed, A., Daugherty, T., … Kwo, P. Y. (2019). THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT). HEPATOLOGY. WILEY.
- DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE
  Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Reddy, K. R., Pan, C. Q., … Afdhal, N. H. (2019). DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE. HEPATOLOGY, 70, 308A–309A.
- LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION
  Reddy, K. R., Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Pan, C. Q., … Afdhal, N. H. (2019). LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION. HEPATOLOGY, 70, 309A.
- CHANGING POPULATION OF LIVER TRANSPLANT RECIPIENTS IN THE ERA OF DIRECT ACTING ANTIVIRAL THERAPY FOR HEPATITIS C VIRUS INFECTION
  Xie, C., Abdallah, M., Wong, R. J., Kwo, P. Y., Thuluvath, P., Asrani, S. K., & Singal, A. K. (2019). CHANGING POPULATION OF LIVER TRANSPLANT RECIPIENTS IN THE ERA OF DIRECT ACTING ANTIVIRAL THERAPY FOR HEPATITIS C VIRUS INFECTION. HEPATOLOGY, 70, 679A.
- HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION
  Schwartz, Z., Schulz, J., King, E., Agarwal, K., Wong, G. L., & Kwo, P. Y. (2019). HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION. HEPATOLOGY. WILEY.
- Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.
  Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., Talwani, R., … Haber, B. A. (2019). Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. International Journal of Women's Health, 11, 617–28.
- CONTINUED THERAPY WITH ABI-H0731+NRTI RESULTS IN SEQUENTIAL REDUCTION/LOSS OF HBV DNA, HBV RNA, HBeAg, HBcrAg AND HBsAg IN HBeAg POSITIVE PATIENTS
  Sulkowski, M. S., Agarwal, K., Fung, S. K., Yuen, M.-F., Ma, X., Lalezari, J. P., … Colonno, R. (2019). CONTINUED THERAPY WITH ABI-H0731+NRTI RESULTS IN SEQUENTIAL REDUCTION/LOSS OF HBV DNA, HBV RNA, HBeAg, HBcrAg AND HBsAg IN HBeAg POSITIVE PATIENTS. HEPATOLOGY. WILEY.
- Novel use of endoscopic morcellator to clear large obscuring clot in patient with upper-GI bleed.
  Gubatan, J., Kwo, P., & Hwang, J. H. (2020). Novel use of endoscopic morcellator to clear large obscuring clot in patient with upper-GI bleed. VideoGIE : an Official Video Journal of the American Society for Gastrointestinal Endoscopy, 5(2), 58–60.
- Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs)
  Prabhakar, V., Lutchman, G., Ahmed, A., Nguyen, M. H., Daugherty, T., & Kwo, P. (2019). Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs). AMERICAN JOURNAL OF GASTROENTEROLOGY, 114, S553–S554.
- Novel Use of EndoRotor (R) Device to Clear Large Obscuring Clot in Patient With Upper Gastrointestinal Bleed
  Gubatan, J., Kwo, P., & Hwang, J. H. (2019). Novel Use of EndoRotor (R) Device to Clear Large Obscuring Clot in Patient With Upper Gastrointestinal Bleed. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter?
  Kwong, A. J., & Kwo, P. Y. (2020). Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Alimentary Pharmacology & Therapeutics, 51(7), 739–40.
- Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
  Saab, S., Bernstein, D., Hassanein, T., Kugelmas, M., & Kwo, P. (2020). Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. Journal of Clinical Gastroenterology.
- DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
  Verna, E. C., Morelli, G., Terrault, N. A., Lok, A. S., Lim, J. K., Di Bisceglie, A. M., … Reddy, K. R. (2020). DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology.
- A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
  Lawitz, E., Gane, E., Ruane, P., Herring, R., Younes, Z. H., Kwo, P., … Loomba, R. (2019). A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. SWISS MEDICAL WEEKLY. E M H SWISS MEDICAL PUBLISHERS LTD.
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies.
  Yao, B. B., Fredrick, L. M., Schnell, G., Kowdley, K. V., Kwo, P. Y., Poordad, F., … Asselah, T. (2020). Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies. Liver International : Official Journal of the International Association for the Study of the Liver.
- HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL
  Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., … Afdhal, N. (2020). HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL. VALUE IN HEALTH. ELSEVIER SCIENCE INC.
- Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
  Nangia, G., Vierling, J. M., Kwo, P., Brown, D. D., Klopfer, S. O., Robertson, M. N., … Reddy, K. R. (2020). Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials. Journal of Viral Hepatitis.
- Viral Hepatitis Other than A, B, and C: Evaluation and Management.
  Cheung, A., & Kwo, P. (2020). Viral Hepatitis Other than A, B, and C: Evaluation and Management. Clinics in Liver Disease, 24(3), 405–19.
- Sustained Virologic Remission in an 8-Month-Old Pediatric Patient with Carbamoyl Phosphate Synthetase I Deficiency and Hepatitis C Infection Using Direct Acting Antivirals Prior to Liver Transplant.
  Huang, A. C., Beadles, A., Romero, D., Berquist, W., Bensen, R., Kwo, P., & Mckenzie, R. B. (2020). Sustained Virologic Remission in an 8-Month-Old Pediatric Patient with Carbamoyl Phosphate Synthetase I Deficiency and Hepatitis C Infection Using Direct Acting Antivirals Prior to Liver Transplant. Journal of Pediatric Gastroenterology and Nutrition.
- Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study.
  Kim, D., Adeniji, N., Latt, N., Kumar, S., Bloom, P. P., Aby, E. S., … Dhanasekaran, R. (2020). Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.
- More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.
  Kwo, P., & Dronamraju, D. (2020). More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis. Clinical and Molecular Hepatology.
- Improving Liver Transplant (LT) Waitlist Attrition
  Concepcion, W., Ahmed, A., Tulu, Z., Hogan, L., Bonham, A., Gallo, A., … Esquivel, C. (2020). Improving Liver Transplant (LT) Waitlist Attrition. AMERICAN JOURNAL OF TRANSPLANTATION. WILEY.
- Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome.
  Adeniji, N., Arjunan, V., Prabhakar, V., Tulu, Z., Kambham, N., Ahmed, A., … Dhanasekaran, R. (2020). Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome. Clinical Transplantation, e14128.
- THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY
  Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W. R., Kwong, A. J., … Kwo, P. Y. (2020). THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY. HEPATOLOGY. WILEY.
- PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY
  Adeniji, N., Kim, D., Latt, N. L., Kumar, S., Bloom, P. P., Aby, E. S., … Dhanasekaran, R. (2020). PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY. HEPATOLOGY. WILEY.
- OUTCOMES AFTER HOSPITALIZATION WITH ACUTE DECOMPENSATION DUE TO ALCOHOL-RELATED LIVER DISEASE
  Kwong, A. J., Goel, A., Daugherty, T., Kwo, P. Y., & Kim, W. R. (2020). OUTCOMES AFTER HOSPITALIZATION WITH ACUTE DECOMPENSATION DUE TO ALCOHOL-RELATED LIVER DISEASE. HEPATOLOGY. WILEY.
- ANALYSIS OF LONGER-TERM SAFETY PROFILE OF THE HEPATITIS B VIRUS CORE INHIBITOR ABI-H0731 IN AN OPEN LABEL EXTENSION STUDY
  Jacobson, I. M., Ma, X., Tuan Nguyen, Schiff, E. R., Yuen, M.-F., Hann, H.-W. L., … Dieterich, D. T. (2020). ANALYSIS OF LONGER-TERM SAFETY PROFILE OF THE HEPATITIS B VIRUS CORE INHIBITOR ABI-H0731 IN AN OPEN LABEL EXTENSION STUDY. HEPATOLOGY. WILEY.
- FEASIBILITY AND EFFICACY OF NOREPINEPHRINE IN THE NON-ICU SETTING FOR TREATMENT OF HEPATORENAL SYNDROME
  Kwong, A. J., Cheng, X., Kwo, P. Y., Wang, U., & Kim, W. R. (2020). FEASIBILITY AND EFFICACY OF NOREPINEPHRINE IN THE NON-ICU SETTING FOR TREATMENT OF HEPATORENAL SYNDROME. HEPATOLOGY. WILEY.
- HEPATITIS C SCREENING IN POST-BABY BOOMER GENERATION AMERICANS: ONE SIZE DOES NOT FIT ALL
  Sriponapun, P., Kim, W. R., Udompap, P., Mannalithara, A., Kwong, A. J., Goel, A., & Kwo, P. Y. (2020). HEPATITIS C SCREENING IN POST-BABY BOOMER GENERATION AMERICANS: ONE SIZE DOES NOT FIT ALL. HEPATOLOGY. WILEY.
- Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B.
  Sripongpun, P., Kim, W. R., Mannalithara, A., Kwong, A., Daugherty, T., Goel, A., & Kwo, P. Y. (2020). Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association.
- Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
  Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P., Russo, M., Shiffman, M. L., … Abdelmalek, M. (2020). Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American Journal of Gastroenterology.
- Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors.
  Adeniji, N., Arjunan, V., Prabhakar, V., Mannalithara, A., Ghaziani, T., Ahmed, A., … Dhanasekaran, R. (2020). Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
- Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
  Abdallah, M. A., Kuo, Y.-F. F., Asrani, S., Wong, R. J., Ahmed, A., Kwo, P., … Singal, A. K. (2020). Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. Journal of Hepatology.
- Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation
  Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2020). Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. HEPATOLOGY COMMUNICATIONS.
- Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis
  John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., … Kwo, P. Y. (2020). Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Characterizing Ascites in Subjects With Nonhepatic Solid Tumors
  Alshuwaykh, O., Cheung, A., Goel, A., Dhanasekaran, R., Ahmed, A., Dronamraju, D., … Kwo, P. Y. (2020). Characterizing Ascites in Subjects With Nonhepatic Solid Tumors. AMERICAN JOURNAL OF GASTROENTEROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.
  Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2021). Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. Hepatology Communications, 5(3), 516–525.
- How Clinicians May Use Tests of Hepatic Function Now and In the Future.
  Ghaziani, T. T., & Kwo, P. Y. (2021). How Clinicians May Use Tests of Hepatic Function Now and In the Future. Translational Research : the Journal of Laboratory and Clinical Medicine.
- Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome.
  Kwong, A., Kim, W. R., Kwo, P. Y., Wang, U., & Cheng, X. (2021). Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
- Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis
  Gane, E., Lawitz, E., Herring, R., Younes, Z. H., Ruane, P. J., Aguilar, R., … Harrison, S. A. (2018). Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
- Dynamic Visual Processing in Patients with Decompensated Cirrhosis
  Wong, K., Liston, D., Papademetriou, S., Yeoh, A., Goel, A., Kwo, P., & Okafor, P. (2018). Dynamic Visual Processing in Patients with Decompensated Cirrhosis. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH
  Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P., Schall, R. A., … Harrison, S. (2018). Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir and +/- ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6)
  Agarwal, K., Brown, R. S., Dumas, E. O., McCaughan, G. W., Samuel, D., Terrault, N., … Forns, X. (2017). Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir and +/- ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6). JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study
  Vierling, J. M., Sobhonslidsuk, A., Papatheodoridis, G., Assy, N., Rosenberg, W., Guyader, D., … Kwo, P. (2017). Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
  Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., … Forns, X. (2017). MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection. JOURNAL OF HEPATOLOGY. ELSEVIER SCIENCE BV.
- Current and future strategies for the treatment of chronic hepatitis C.
  Alshuwaykh, O., & Kwo, P. Y. (2021). Current and future strategies for the treatment of chronic hepatitis C. Clinical and Molecular Hepatology, 27(2), 246–56.
- Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.
  Dhanasekaran, R., & Kwo, P. Y. (2021). Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. Clinical Liver Disease, 17(3), 169–73.
- Alcoholic Hepatitis and its Many Facets.
  Kwo, P. Y. (2021). Alcoholic Hepatitis and its Many Facets. Clinics in Liver Disease, 25(3), xiii-xiv.
- Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection.
  Gane, E., Sulkowski, M., Ma, X., Nguyen, T., Hann, H.-W., Hassanein, T., … Yuen, M.-F. (2021). Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
  Singal, A. K., Kwo, P., Kwong, A., Liangpunsakul, S., Louvet, A., Mandrekar, P., … Shah, V. H. (2021). Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology (Baltimore, Md.).
- THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE
  Alshuwaykh, O., Goel, A., Ghaziani, T. T., Daugherty, T., Dhanasekaran, R., Ahmed, A., … Kwo, P. Y. (2021). THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE. HEPATOLOGY. WILEY.
- PSYCHOSOCIAL PREDICTORS OF ALCOHOL RELAPSE AMONG LIVER TRANSPLANT CANDIDATES WITH ALCOHOL-RELATED LIVER DISEASE
  Sedki, M., Kwo, P. Y., Ahmed, A., Hussain, F., Kwong, A. J., & Goel, A. (2021). PSYCHOSOCIAL PREDICTORS OF ALCOHOL RELAPSE AMONG LIVER TRANSPLANT CANDIDATES WITH ALCOHOL-RELATED LIVER DISEASE. HEPATOLOGY. WILEY.
- STANFORD INTEGRATED PSYCHOSOCIAL ASSESSMENT FOR TRANSPLANT (SIPAT) IS SUPERIOR TO SALT AND HRAR IN IDENTIFYING LT CANDIDATES WITH ALD AT LOW RISK OF RELAPSE
  Sedki, M., Kwo, P. Y., Ahmed, A., Hussain, F., Kwong, A. J., & Goel, A. (2021). STANFORD INTEGRATED PSYCHOSOCIAL ASSESSMENT FOR TRANSPLANT (SIPAT) IS SUPERIOR TO SALT AND HRAR IN IDENTIFYING LT CANDIDATES WITH ALD AT LOW RISK OF RELAPSE. HEPATOLOGY. WILEY.
- PREDICTORS OF ELEVATED LIVER TESTS DURING COVID-19 SHELTER IN PLACE IN CHRONIC LIVER DISEASE PATIENTS
  Alshuwaykh, O., Wong, R. J., Kim, W. R., Torok, N. J., Jiang, J. K., & Kwo, P. Y. (2021). PREDICTORS OF ELEVATED LIVER TESTS DURING COVID-19 SHELTER IN PLACE IN CHRONIC LIVER DISEASE PATIENTS. HEPATOLOGY. WILEY.
- HBV PGRNA AND DNA BOTH REBOUND IMMEDIATELY FOLLOWING DISCONTINUATION OF THE CORE INHIBITOR VEBICORVIR DESPITE CONTINUED NRTI TREATMENT IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: FINDINGS FROM A PHASE 2 OPEN LABEL STUDY
  Yuen, M.-F., Ma, X., Hassanein, T. I., Kwo, P. Y., Ma, J., Li, L., … Agarwal, K. (2021). HBV PGRNA AND DNA BOTH REBOUND IMMEDIATELY FOLLOWING DISCONTINUATION OF THE CORE INHIBITOR VEBICORVIR DESPITE CONTINUED NRTI TREATMENT IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: FINDINGS FROM A PHASE 2 OPEN LABEL STUDY. HEPATOLOGY. WILEY.
- IMPACT OF NEW SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY ON POST LIVER TRANSPLANT OUTCOMES AND NUMBER OF KIDNEYS USED
  Waleed, M., Maan, M. H. A., Kuo, Y.-F., Kwo, P. Y., Mahmud, N., Sharma, P., … Singal, A. K. (2021). IMPACT OF NEW SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY ON POST LIVER TRANSPLANT OUTCOMES AND NUMBER OF KIDNEYS USED. HEPATOLOGY. WILEY.
- Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
  Pan, C. Q., Jacobson, I. M., Martin, P., Kwo, P., Lim, J., Han, S.-H. B., … Tong, M. J. (1800). Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. Hepatology (Baltimore, Md.).
- Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.
  Halket, D., Dang, J., Phadke, A., Jayasekera, C., Kim, W. R., Kwo, P., … Goel, A. (2022). Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. Journal of General Internal Medicine.
- Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer.
  Singal, A. K., & Kwo, P. (2022). Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer. Alcoholism, Clinical and Experimental Research.
- First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
  Pan, C. Q., Afdhal, N. H., Ankoma-Sey, V., Bae, H., Curry, M. P., Dieterich, D., … Reddy, K. R. (2022). First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatology Communications.
- Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
  Yuen, M.-F. F., Agarwal, K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H.-W. L., … Sulkowski, M. S. (2022). Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection. Journal of Hepatology.
- Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization.
  Singal, A. K., Kuo, Y.-F., Kwo, P., Mahmud, N., Sharma, P., & Nadim, M. K. (2022). Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization. Clinical Transplantation, e14700.
- Building a better mousetrap: can MELD-Na be improved?
  Kwong, A., Mannalithara, A., Kwo, P., & Kim, W. R. (2020). Building a better mousetrap: can MELD-Na be improved? JOURNAL OF HEPATOLOGY. ELSEVIER.
- Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US
  Sripongpun, P., Goel, A., Mannalithara, A., Kwo, P., & Kim, W. R. (2020). Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C)
  Goel, A., Downing, L., Dang, J., Jayasekera, C., & Kwo, P. (2020). Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C). JOURNAL OF HEPATOLOGY. ELSEVIER.
- Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice
  Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., … Afdhal, N. (2020). Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
  Fung, S., Sulkowski, M., Lalezari, J., Schiff, E. R., Dieterich, D., Hassanein, T., … Yuen, M.-F. (2020). Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression
  Reddy, R., Curry, M., Dieterich, D., Ankoma-Sey, V., Pan, C., Hann, H.-W., … Afdhal, N. (2020). Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
  Sulkowski, M. S., Agarwal, K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H.-W. L., … Yuen, M.-F. (2022). Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection. Journal of Hepatology.
- Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021.
  Ali, S. E., Vutien, P., Bonham, C. A., Landis, C., Kwo, P., Esquivel, C., & Nguyen, M. H. (2022). Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
- Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naive patients with HBeAg positive chronic hepatitis B
  Sulkowski, M. S., Fung, S. K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H.-W. L., … Yuen, M.-F. (2022). Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naive patients with HBeAg positive chronic hepatitis B. JOURNAL OF HEPATOLOGY. ELSEVIER.
- HCV treatment in 2020: How to translate highly effective therapies into elimination strategies.
  Alshuwaykh, O., & Kwo, P. Y. (2020). HCV treatment in 2020: How to translate highly effective therapies into elimination strategies. Hepatology Forum, 1(2), 72–74.
- Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
  Alshuwaykh, O., Daugherty, T., Cheung, A., Goel, A., Dhanasekaran, R., Ghaziani, T. T., … Kwo, P. Y. (2022). Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. Hepatology Communications.
- Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.
  Alshuwaykh, O., Cheung, A., Goel, A., Kwong, A., Dhanasekaran, R., Ghaziani, T. T., … Kwo, P. Y. (2022). Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites. BMC Gastroenterology, 22(1), 410.
- Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US.
  Singal, A. K., Kuo, Y.-F., Reddy, K. R., Bataller, R., & Kwo, P. (2022). Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Alimentary Pharmacology & Therapeutics.
- Final results from the ribavirin pregnancy registry, 2004-2020.
  Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., & Maddrey, W. C. (2022). Final results from the ribavirin pregnancy registry, 2004-2020. Birth Defects Research.
- Portopulmonary Hypertension.
  Lai, Y. K., & Kwo, P. Y. (2023). Portopulmonary Hypertension. Clinics in Liver Disease, 27(1), 71–84.
- Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications.
  Kuo, Y.-F. F., Kwo, P., Wong, R. J., & Singal, A. K. (2023). Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications. Journal of Clinical and Translational Hepatology, 11(1), 130–135.
- CHARACTERISTICS AND CARE OF CHRONIC HEPATITIS B PATIENTS WITH ADVANCED PRACTICE PROVIDERS
  Kam, L., Huang, D., Tobias, A. F., Poon, K., Henry, L., Kwo, P. Y., … Nguyen, M. H. (2022). CHARACTERISTICS AND CARE OF CHRONIC HEPATITIS B PATIENTS WITH ADVANCED PRACTICE PROVIDERS. HEPATOLOGY. WILEY.
- A NOVEL EDUCATIONAL PROGRAM TO ADDRESS MISUNDERSTANDINGS IN APPLYING AASLD HBV TREATMENT GUIDELINES
  Ahn, J., Anderson, S., Dela Cruz, A. C. L., Kwo, P. Y., Nguyen, M. H., & Schwartz, Z. (2022). A NOVEL EDUCATIONAL PROGRAM TO ADDRESS MISUNDERSTANDINGS IN APPLYING AASLD HBV TREATMENT GUIDELINES. HEPATOLOGY. WILEY.
- THE IMPACT OF TELEHEALTH USAGE ON LIVER TRANSPLANT EVALUATIONS DURING COVID-19
  Jowell, A., Kwong, A. J., Daugherty, T., & Kwo, P. Y. (2022). THE IMPACT OF TELEHEALTH USAGE ON LIVER TRANSPLANT EVALUATIONS DURING COVID-19. HEPATOLOGY. WILEY.
- Epidemiology and Disease Burden of Alcohol Associated Liver Disease.
  Aslam, A., & Kwo, P. Y. (2023). Epidemiology and Disease Burden of Alcohol Associated Liver Disease. Journal of Clinical and Experimental Hepatology, 13(1), 88–102.
- Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know.
  Wong, F., & Kwo, P. (2023). Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know. The American Journal of Gastroenterology.
- Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis.
  Achalu, S., Berry, R., Wei, M. T., Banerjee, S., Ghanouni, P., Kambham, N., & Kwo, P. Y. (2023). Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis. ACG Case Reports Journal, 10(4), e01044.
- Clinical trials reimagined.
  Kwo, P. Y., & Patel, T. (2023). Clinical trials reimagined. Hepatology (Baltimore, Md.).
- Accuracy of Information Provided by ChatGPT Regarding Liver Cancer Surveillance and Diagnosis.
  Cao, J. J., Kwon, D. H., Ghaziani, T. T., Kwo, P., Tse, G., Kesselman, A., … Tse, J. R. (2023). Accuracy of Information Provided by ChatGPT Regarding Liver Cancer Surveillance and Diagnosis. AJR. American Journal of Roentgenology.
- Viral Hepatitis and Acute-on-Chronic Liver Failure.
  Bhatti, T. K., Singal, A. K., & Kwo, P. Y. (2023). Viral Hepatitis and Acute-on-Chronic Liver Failure. Clinics in Liver Disease, 27(3), 617–630.
- Hepatitis C Screening in Post-Baby Boomer Generation Americans: One Size Does Not Fit All.
  Sripongpun, P., Udompap, P., Mannalithara, A., Downing, N. L., Vidovszky, A. A., Kwong, A. J., … Kim, W. R. (2023). Hepatitis C Screening in Post-Baby Boomer Generation Americans: One Size Does Not Fit All. Mayo Clinic Proceedings, 98(9), 1335–1344.
- Use and outcomes of hepatitis B virus positive grafts for renal or heart transplantation in the US (1999-2021)
  Singal, A., Reddy, K. R., Mindie Nguyen, Younossi, Z. M., Kwo, P. Y., & Kuo, Y.-F. (2023). Use and outcomes of hepatitis B virus positive grafts for renal or heart transplantation in the US (1999-2021). JOURNAL OF HEPATOLOGY. ELSEVIER.
- Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
  Clark, V., Strange, C., Strnad, P., Sanchez, A., Kwo, P. Y., Pereira, V. M., … Loomba, R. (2023). Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study. JOURNAL OF HEPATOLOGY. ELSEVIER.
- Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models.
  Sedki, M., Kwong, A., Bhargava, M., Ahmed, A., Daugherty, T., Kwo, P., … Goel, A. (2023). Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models. Transplantation.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Specializing In

Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis C Treatment
Hepatitis D
Liver Disease Prevention
Liver Transplant
Polycystic Liver Disease
Primary Biliary Cirrrhosis
Primary Sclerosing Cholangitis

Practice Locations

Liver Transplant Clinic in Pleasanton Pleasanton, CA

Pleasanton, CA

Liver Transplant Clinic in Pleasanton

5565 W Las Positas Blvd

Pleasanton , CA 94588

(650) 498-7999

More Clinic Information

Advanced Endoscopy in Palo Alto Stanford, CA

Stanford, CA

Advanced Endoscopy in Palo Alto

300 Pasteur Drive, Ground Floor

Stanford , CA 94305

(650) 736-5555

More Clinic Information

Hereditary Hemorrhagic Telangiectasia Center of Excellence Stanford, CA

Stanford, CA

Hereditary Hemorrhagic Telangiectasia Center of Excellence

300 Pasteur Dr

Stanford , CA 94305

(650) 498-1764

More Clinic Information

Stanford Health Care Tri-Valley Pleasanton, CA

Pleasanton, CA

Stanford Health Care Tri-Valley

5565 W Las Positas Blvd

Pleasanton , CA 94588

(925) 847-3000

More Clinic Information

Liver (Hepatology) Clinic in Fremont Fremont, CA

Fremont, CA

Liver (Hepatology) Clinic in Fremont

2557 Mowry Ave, Ste 34

Fremont , CA 94538

(650) 725-1988

More Clinic Information

Liver (Hepatology) Clinic in Redwood City Redwood City, CA

Redwood City, CA

Liver (Hepatology) Clinic in Redwood City

420 Broadway St, Pavilion D 2nd Fl

Redwood City , CA 94063

(650) 498-7999

More Clinic Information

Digestive Health Center in Redwood City Redwood City, CA

Redwood City, CA

Digestive Health Center in Redwood City

420 Broadway Street, Pavilion D 2nd Floor

Redwood City , CA 94063

(650) 736-5555

More Clinic Information

Liver (Hepatology) Clinic in Fresno Fresno, CA

Fresno, CA

Liver (Hepatology) Clinic in Fresno

7130 N Millbrook Ave

Fresno , CA 93720

(650) 725-1988

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(70 Ratings)

Overall Rating

4.9/5

View Ratings by Category

5.0/5

Friendliness

4.9/5

Explanations

4.9/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(199 reviews)

Very informative

Oct 2024

•

Verified SHC Patient

I appreciate the quality of the information that I have received from the friendly medical team

Oct 2024

•

Verified SHC Patient

Great

Sep 2024

•

Verified SHC Patient

Thank you Dr. for your attention and wisdom regarding my health. See you in 6 months via video.

Sep 2024

•

Verified SHC Patient

Dr Kwo and his team are excellent. The knowledge and commitment to take care of my health take from me the overwhelming sensation of having incurable health conditions

Jul 2024

•

Verified SHC Patient

Thank you

Jul 2024

•

Verified SHC Patient

He a very good doctor

Jun 2024

•

Verified SHC Patient

Great doctor!

Jun 2024

•

Verified SHC Patient

Best!

Jun 2024

•

Verified SHC Patient

Dr. Kwo answers all of my questions and is straight forward with me. He is willing to do whatever needs to be done and what is most convenient for me. I appreciate all of that very much.

May 2024

•

Verified SHC Patient

Excellent, articulate and proactive! Thank you!

May 2024

•

Verified SHC Patient

Good Doctor gives me great advice

May 2024

•

Verified SHC Patient

He is ASWOME!

May 2024

•

Verified SHC Patient

DR Kwo is always considerate and informative regarding my health concerns. He always answers any questions in a manner I can understand them. I feel comfortable with him as my physician.

Apr 2024

•

Verified SHC Patient

Very polite and professional.

Apr 2024

•

Verified SHC Patient

Excellent

Apr 2024

•

Verified SHC Patient

Dr Paul Kwo is very friendly and tries his best to provide answer to all my queries.

Apr 2024

•

Verified SHC Patient

I want to give my gratitude to dr. Kwo who works very hard on me and save my life, thanks to him and his team Im alive, thank you thank you thank you!!!

Apr 2024

•

Verified SHC Patient

He's pretty good at answering all your questions and having a medical plan.

Mar 2024

•

Verified SHC Patient

Dr. Kwo is very caring, knowledgeable and professional. He answers all my questions adequately and patiently. He is compassionate and can sympathize with his patient. I recommend him highly.

Mar 2024

•

Verified SHC Patient

Dr Kwo is a superb physician who saved my life.

Mar 2024

•

Verified SHC Patient

Excellent doctor and advocate

Mar 2024

•

Verified SHC Patient

I think heâ€™s a great doctor and heâ€™s taking care of me pretty well and I donâ€™t have anything bad to say about him. I think him wearing a mask is ridiculous when he touches his face after he takes off the mask, maybe you guys need more hand sanitizer

Feb 2024

•

Verified SHC Patient

Amazing doctor and glad to be in his advise

Feb 2024

•

Verified SHC Patient

Extremely knowledgeable and helpful.

Feb 2024

•

Verified SHC Patient

outstanding. the best

Feb 2024

•

Verified SHC Patient

Dr. Kwo is professional and knowledgeable. He speaks in way that keeps me focused and well informed on my diagnosis. He listens, and responds.. He answers questions. He is thoughtful He is very Kind

Jan 2024

•

Verified SHC Patient

Super good experience. Dr and staff member are very efficient, explicit, and pleasant.

Jan 2024

•

Verified SHC Patient

Thank God for him and his staff

Jan 2024

•

Verified SHC Patient

Extremely helpful and spoke to me in a way I was able to fully understand.

Jan 2024

•

Verified SHC Patient

Dr. Paul is the best Dr. and all I can say is thank you Dr. Paul.

Jan 2024

•

Verified SHC Patient

A great doctor and great medical practioner. Thoroughly involved in the treatment process and very humble with the patient Thank you doc for all your involvement in treatment of my liver ailment and connected issu Thanks

Jan 2024

•

Verified SHC Patient

Great doctorâ€¦lucky to have him as my doctor

Dec 2023

•

Verified SHC Patient

Dr. Kwo is a gentleman. He is knowledgeable, kind and professional. The treatment I received from him has been excellent. His conversation was shout but succinct and to the point. Looking forward to his follow up care.

Nov 2023

•

Verified SHC Patient

Personable, helpful, respectful.

Nov 2023

•

Verified SHC Patient

He was very caring.

Sep 2023

•

Verified SHC Patient

Excellent doctor!!

Sep 2023

•

Verified SHC Patient

Very compationate and skilful doctor.

Sep 2023

•

Verified SHC Patient

Dr Kwo, in my opinion is the BEST! He has always been very caring. I talk to others about the love, the care and attention of the medical team at Stanford! I always thank God for doctors like Dr Kwo. I truly love him!!

Sep 2023

•

Verified SHC Patient

thanks for your time and help

Sep 2023

•

Verified SHC Patient

Heâ€™s a really good doctor. Heâ€™s very thorough.

Sep 2023

•

Verified SHC Patient

Always a pleasure to deal w Dr Kwo

Aug 2023

•

Verified SHC Patient

A very thoughtful and responsive doctor!

Aug 2023

•

Verified SHC Patient

He is a great doctor

Aug 2023

•

Verified SHC Patient

Dr. Paul Kwo is personable, patient, and demonstrates an impressive breadth of knowledge.

Jul 2023

•

Verified SHC Patient

Dr. Kwo is great. I feel very fortunate to have him as my doctor.

Jul 2023

•

Verified SHC Patient

Dr. Kwo is an amazing doctor. I appreciate him immensely.

Jul 2023

•

Verified SHC Patient

Nicr through doctor. Explained everything and was complementary.

Jul 2023

•

Verified SHC Patient

Asked me a lot f questions. Loved that. I need answers to see what is going on with my health.

Jun 2023

•

Verified SHC Patient

I have been seeing Dr. Kwo for a few years and would highly recommend him to anyone; he explains in detail and most respectful.

Jun 2023

•

Verified SHC Patient

Dr. Paul Kwo was concerned about my hepatitis b. He is very helpful Doctor.

May 2023

•

Verified SHC Patient

I feel very lucky and blessed to have Dr. Kwo as my hepatologist. He is certainly at the top in his field.

May 2023

•

Verified SHC Patient

Dr. Kwo had a pleasent demeanor, answered my questions.

May 2023

•

Verified SHC Patient

Best caring, understanding doctor

May 2023

•

Verified SHC Patient

Great attitude and extremely knowledgeable

May 2023

•

Verified SHC Patient

Excellent

May 2023

•

Verified SHC Patient

He was real easy to speak to and was pretty clear about what steps would be next.

May 2023

•

Verified SHC Patient

On top of their game. Smart, quick, pleasant.

Apr 2023

•

Verified SHC Patient

Wonderful

Apr 2023

•

Verified SHC Patient

Because he was easy to talk with, I soon felt fairly comfortable during the appointment.

Apr 2023

•

Verified SHC Patient

Very conscientious and concerned about my health.

Apr 2023

•

Verified SHC Patient

Excellent

Mar 2023

•

Verified SHC Patient

Enjoy having dr kwo as my provider. He is thorough and not overly cautious. He takes in to consideration that I live in Roseville and works to schedule any follow up where it is most convenient for me.

Mar 2023

•

Verified SHC Patient

Dr. Kwo is always pleasant, thoughtful and clinically excellent.

Mar 2023

•

Verified SHC Patient

Dr. Kwo is a knowledgeable, empathetic, educational provider. He discussed and relayed all information in an easy to understand manner and suggested additional resources that would enable me to delve further into guideline recommendations, which I really appreciated. He relayed the benefits of various testing modalities, the frequency with which I should be tested and recommended additional testing to address all my concerns. I would recommend Dr. Kwo to anyone seeking a liver expert

Mar 2023

•

Verified SHC Patient

He took the time to learn so much about my history and see me as an individual. Very pleased.

Mar 2023

•

Verified SHC Patient

GREAT DOCTOR!!! He has been helping me since 2017 with my liver cancer issues.

Feb 2023

•

Verified SHC Patient

Dr. Kwo is amazing. Heâ€™s extremely kind and flexible. I want to thank him for giving me quality care. I also want to thank him for giving me my life back.

Feb 2023

•

Verified SHC Patient

Thorough and clear Seemed kind and caring

Jan 2023

•

Verified SHC Patient

Dr Kwo makes the patient feel confident and he respect me as a person. He is serious but at same time makes the patient feel comfortable to discuss any matter about the health condition. I am very grateful to be under his care.

Dec 2022

•

Verified SHC Patient

Very attentive and informative

Nov 2022

•

Verified SHC Patient

Very easy to talk to and listen to what I had to say

Nov 2022

•

Verified SHC Patient

Dr. Kwo was actually early for the appt and was very informative and helpful! Very much recommend.

Nov 2022

•

Verified SHC Patient

Excellent Doctor! He saved my life!

Nov 2022

•

Verified SHC Patient

I know he is extremely highly regarded in his field and I am in very good hands with his care. This makes me feel relieved that I don't have to worry. I'm very glad to be his patient.

Nov 2022

•

Verified SHC Patient

Very good doctor and advocate

Nov 2022

•

Verified SHC Patient

Great doctor very professional and explains everything perfectly...his bedside manners are top notch as well as his staff.

Oct 2022

•

Verified SHC Patient

Dr Kwo is the best.

Oct 2022

•

Verified SHC Patient

THANK YOU

Sep 2022

•

Verified SHC Patient

Dr. Kwo as usually was courteous professional, and answered all my health questions.

Sep 2022

•

Verified SHC Patient

Excellent. Addressed all my questions and concerns.

Sep 2022

•

Verified SHC Patient

Dr Kwo Always listens and suggests things to help with my health

Aug 2022

•

Verified SHC Patient

Dr. Kwo was clear and paying attention on my medical case; won my confidence in him.

Aug 2022

•

Verified SHC Patient

Great doctor! Very knowledgeable, up to date information, competent, and confident.

Aug 2022

•

Verified SHC Patient

He is very easy to work with. He is thorough and answers questions in a way that is easy to understand.

Aug 2022

•

Verified SHC Patient

Thoughtful Dr. Who really explains when questions are asked.

Aug 2022

•

Verified SHC Patient

Thank you!!

Aug 2022

•

Verified SHC Patient

Heâ€™s a very excellent doctor I highly recommend him sometimes I wish you would answer more of my questions he seems to be more of a rush these days but I understand because of Covid

Jul 2022

•

Verified SHC Patient

Excellent doctor who explained everything very clearly and answered all of my questions.

Jul 2022

•

Verified SHC Patient

Very good Iâ€™m happy

Jul 2022

•

Verified SHC Patient

Dr Kwo is exceptional. He has been my Dr since my LT and I could not be happier to have him monitoring my case. He is caring, fastidious, detailed and patient when I ask a question or need further explanation on any detail.

Jul 2022

•

Verified SHC Patient

Dr. Kwo is always the greatest doctor I've seen. I heartily appreciate, respect and admire him. It's my best luck to have Dr. Kwo as my gastroenterologist, indeed. Thank God so much for leading me to find Dr. Kwo taking care of my health. Prior to seeing Dr. Kwo, I'd searched for a good doctor to treat my livers' issues for more than decade but failed. I always regard having Dr. Kwo's kind and trustful care is one of the best blessings God has given me in the life. Dr. Kwo, thank you so much for all!

Jun 2022

•

Verified SHC Patient

I like working with Dr Kwo. He listens well and is clear in his comments. He seems like a nice person.

Jun 2022

•

Verified SHC Patient

Dr. Kwo is a fantastic doctor - thorough, knowledgeable, kind.

Jun 2022

•

Verified SHC Patient

Dr. Paul Kwo has been following my conditions for a few years now and I appreciate his expertise. I look forward to an annual liver check-up next year.

Jun 2022

•

Verified SHC Patient

He is very attentive and knowledgeable about what is happening and knowledgeable about PSC. Feel like he truly cares about my health

May 2022

•

Verified SHC Patient

Great doctor!!!

May 2022

•

Verified SHC Patient

Amazing physician! Heâ€™s the best doctor Iâ€™ve ever had

May 2022

•

Verified SHC Patient

Excellent Doctor, answered all my questions.

Apr 2022

•

Verified SHC Patient

A very detailed, courteous, knowledgeable & compassionate doctor.

Apr 2022

•

Verified SHC Patient

Wonderful, excellent doctor!

Apr 2022

•

Verified SHC Patient

Lab tech kept complaining about how hard it is to stick me

Apr 2022

•

Verified SHC Patient

Everybody was on time and when electricity went out Dr. Kwo called me immediately.

Apr 2022

•

Verified SHC Patient

Dr. Kwo asked the right questions and answered my questions.

Mar 2022

•

Verified SHC Patient

My visit was very informative, and satisfing. Dr. Kwo was a caring doctor and wanted to answer all my questions and help to find the best path for me to follow to be better. I was very happy to have found him and was able to have a doctors visit with him.

Mar 2022

•

Verified SHC Patient

Good doctor

Mar 2022

•

Verified SHC Patient

The best

Mar 2022

•

Verified SHC Patient

Clear communicator and thoughtful.

Feb 2022

•

Verified SHC Patient

Dr. Kwo answered my all my questions. Reviews my tests and gave me suggestions on an issue. Outlined next steps and relayed the future tests ordered. Thank You Dr. Kwo

Feb 2022

•

Verified SHC Patient

Very polite and easy to speak with

Feb 2022

•

Verified SHC Patient

Dr Kwo is a wonderful doctor. He is extremely detailed, knowledgable, helpful, concerned and cares very much. I feel quite fortunate to have had Dr Kwo assigned to my care. He makes seeing a doctor a pleasant experience.

Feb 2022

•

Verified SHC Patient

Excellent communicator, he was very thorough when reviewing my history, some going back 20 years. His approach seemed appropriate in that we are not shot gun blasting to further define the problem, but having a few more tests to verify.

Feb 2022

•

Verified SHC Patient

Dr kwo is a excellent doctor

Jan 2022

•

Verified SHC Patient

Very attentive & intelligent about my PBC.

Jan 2022

•

Verified SHC Patient

I think Dr. Kwo is an amazing doctor. He is extremely thorough with his job. He is extremely considerate as well. He cares for the quality of life for his patients and does his best to support it. XO Some people might misunderstand his demeanor as a bit stand off ish but I think heâ€™s just a bit shy and reserved. He is a more mature doctor.

Jan 2022

•

Verified SHC Patient

Very knowledgeable, kind and thorough.

Jan 2022

•

Verified SHC Patient

Great job I appreciate your business guys

Dec 2021

•

Verified SHC Patient

Detailed and thorough

Dec 2021

•

Verified SHC Patient

Dr, Kwo was miles above my expectation. He is inclusive, patient, compassionate and inquisitive.

Dec 2021

•

Verified SHC Patient

I like working with Dr Kwo. Heâ€™s clear, accessible, thoughtful. He is professional and kind. He asks if I understand and if I agree to his recommendations. I feel we are a ream.

Dec 2021

•

Verified SHC Patient

I really like Paul Kwo he is very professional

Dec 2021

•

Verified SHC Patient

Excellent patient care

Nov 2021

•

Verified SHC Patient

Dr. Kwo is just awesome for all. I heartily appreciate for his kind care and support. Many thanks for all + Best regards!

Nov 2021

•

Verified SHC Patient

Dr. Kwo is a very caring doctor. Heâ€™s concerned on my health and gives me good advice and the medicine that I should buy.

Nov 2021

•

Verified SHC Patient

I have seen him once and had a video/phone chat with him. He is interested in my case and seems to really want to help me. I'm willing to listen and follow his advice. I've waited a long time to find a doctor who is willing to get to root of the problem and not guess it could be this or that. I am looking forward to meeting with him again. Thank You!

Oct 2021

•

Verified SHC Patient

Doctor Paul Kwo is an Excellent DOCTOR !

Oct 2021

•

Verified SHC Patient

Excellent MD, took the time to answer my questions and provided a sound plan.

Sep 2021

•

Verified SHC Patient

He is my doctor and I believe in him very much.

Sep 2021

•

Verified SHC Patient

Professional, kind and makes you feel comfortable.

Sep 2021

•

Verified SHC Patient

Great doctor

Sep 2021

•

Verified SHC Patient

I appreciate Dr. Kwoâ€™s excellent care and that he takes time to answer my questions.

Aug 2021

•

Verified SHC Patient

He is very thorough and listens well to what I had to say.

Aug 2021

•

Verified SHC Patient

I appreciate the very complete evaluation.

Aug 2021

•

Verified SHC Patient

Answered my questions and provided a plan

Aug 2021

•

Verified SHC Patient

He's great.

Jul 2021

•

Verified SHC Patient

Dr. Kwo was outstanding. Good listener, professional, and was kind and caring.

Jul 2021

•

Verified SHC Patient

Doctor Kwo, the strength in your voice was giving us power to fight the sickness. Thank you for everything youâ€™ve done for us and we are so happy we have found a doctor like you.

Jun 2021

•

Verified SHC Patient

He is great

Jun 2021

•

Verified SHC Patient

Dr. Kwo is absolutely the most caring, empowering, amazing doctor I know. He takes great care to listen to patients needs and to come up with plan Of care that is patient-centered. I feel lucky to have him as my provider.

Jun 2021

•

Verified SHC Patient

He is wonderful

May 2021

•

Verified SHC Patient

Helpful and caring doctor.

May 2021

•

Verified SHC Patient

The video visit was a success. It would be even better if someone could inform me that you were behind schedule.

May 2021

•

Verified SHC Patient

To keep being how he is with me, he shows me that he cares and now a days this is very important. Thank you very much, and God bless you Dr. Kwo

May 2021

•

Verified SHC Patient

Very professional and knowledgeable.

May 2021

•

Verified SHC Patient

He is wonderful!

May 2021

•

Verified SHC Patient

answers all my questions thoroughly and very patient

May 2021

•

Verified SHC Patient

Dr Kwo is excellent. So thorough, straightforward (which is my favorite!) and really cares about me and my health. I feel lucky to have him as my dr.

May 2021

•

Verified SHC Patient

Dr. Kwo as always was professional and courteous, asked and answered all questions to my satisfaction/ understanding.

May 2021

•

Verified SHC Patient

EXCELLENT DOCTOR!!!!!

Apr 2021

•

Verified SHC Patient

Fabulous doctor. Very informative, understanding of my concerns, answered questions in plain terms.

Apr 2021

•

Verified SHC Patient

Good.

Apr 2021

•

Verified SHC Patient

I was very happy with the visit.

Mar 2021

•

Verified SHC Patient

Dr. Kwo is a very friendly and professionally care provider that I'm lucky to have at the Liver Clinic.

Mar 2021

•

Verified SHC Patient

my doctor is very good at listening to all my health concern issues.

Mar 2021

•

Verified SHC Patient

Very good thank you very much.

Feb 2021

•

Verified SHC Patient

Fair.

Jan 2021

•

Verified SHC Patient

Everything was just excellent. Doctor such an amazing person, as well as the team made an outstanding job!! Thank you so much! Appreciate a great experience.

Nov 2020

•

Verified SHC Patient

Dr. Kwo is fantastic!

Sep 2020

•

Verified SHC Patient

Good.

Jul 2020

•

Verified SHC Patient

Continue to receive outstanding care from Dr. Kwo.

Jul 2020

•

Verified SHC Patient

Dr. Kwo was very friendly & informative.

Mar 2020

•

Verified SHC Patient

Dr. Two has always been great..

Feb 2020

•

Verified SHC Patient

Dr. Kwo is the best!

Jan 2020

•

Verified SHC Patient

Dr. Kwo is great!

Dec 2019

•

Verified SHC Patient

Dr. Kwo, Paul is excellent.

Nov 2019

•

Verified SHC Patient

Dr. Kwo is outstanding!!

Oct 2019

•

Verified SHC Patient

The 2 doctors were fantastic!!!

Oct 2019

•

Verified SHC Patient

You need one more level - outstanding.

Aug 2019

•

Verified SHC Patient

Fantastic, thoughtful and very patient doctor.

Aug 2019

•

Verified SHC Patient

Dr. Kwo is the best specialist you have on board. He is thorough. A great communicator. Good listener. Compassionate and a good fit for Stanford. I am so lucky to have him as my liver specialist.

Aug 2019

•

Verified SHC Patient

an excellent provider

Aug 2019

•

Verified SHC Patient

Dr K. is the best!

Jul 2019

•

Verified SHC Patient

Good.

Jul 2019

•

Verified SHC Patient

Very nice

Jul 2019

•

Verified SHC Patient

Dr Kwo is absolutely fantastic, the assistant Jonathan is a great guy too!

Jun 2019

•

Verified SHC Patient

good

Jun 2019

•

Verified SHC Patient

Excellent.

Jun 2019

•

Verified SHC Patient

OUTSTANDING CARE GIVER

May 2019

•

Verified SHC Patient

My care provide is excellent.

Apr 2019

•

Verified SHC Patient

DR. KWO IS OUTSTANDING.

Feb 2019

•

Verified SHC Patient

Dr. Kwo has been fantastic every step of the way. I am very fortunate to have him on my team!!!!

Jan 2019

•

Verified SHC Patient

Dr.Kwo is the best !!!!

Nov 2018

•

Verified SHC Patient

After meeting with dr. told to wait in waiting area - no one assisted us - we had to ck. w/staff & they didn't know. Had questions still - prescription?s, lab was needed & not told.

Aug 2018

•

Verified SHC Patient

Outstanding.

Jul 2018

•

Verified SHC Patient

Dr. Kwo is the perfect doctor for me. He is reassuring, personable, and compassionate. A great addition to Stanford Liver Clinic.

Jun 2018

•

Verified SHC Patient

Dr. Kwo is a amazing physician - incredibly knowledgeable, caring, clear & concise in his explanations. Have total confidence in his ability to diagnose and help me resolve my problem.

Apr 2018

•

Verified SHC Patient

I felt much better about my condition and treatment after my visit. I didn't understand a few things physician said, but he had no problem rephrasing.

Mar 2018

•

Verified SHC Patient

Dr. Kwo was open and honest with me concerning my condition and showed genuine concern for my well being and the gravity of my condition.

Feb 2018

•

Verified SHC Patient

Wonderful doctor.

Feb 2018

•

Verified SHC Patient

Dr. Kwo is an exceptional care provider - he is very knowledgeable but also very caring. I have complete confidence in him.

Feb 2018

•

Verified SHC Patient

Dr. Paul Kwo is excellent!!!!!

Dec 2017

•

Verified SHC Patient

good

Dec 2017

•

Verified SHC Patient

Dr. Paul Kwo is very polite, friendly, and explained my options.

Oct 2017

•

Verified SHC Patient

Dr. Kwo is the REASON we are at Stanford Health - especially after all the radiology scheduling issues!

Sep 2017

•

Verified SHC Patient

He's gentle. Listens carefully and clarifies worries in a simple easy to understand way.

Sep 2017

•

Verified SHC Patient

I love the responsiveness, care and attention to details of my visit. The staff and care providers were all excellent and have very professional demeanors.

Aug 2017

•

Verified SHC Patient

Dr. Kwo is an excellent caregiver. He is intelligent, informed of current medical research, and persistent in researching the details on my mom's rare condition. He is patient in addressing all of my mom's concerns and patient in having to repeat himself to reassure her. Despite his being the Director of the department, I never feel like he's in a rush and that he gives my mom and me his full attention.

Aug 2017

•

Verified SHC Patient

Thank you, Dr. Kwo. We deeply appreciated your guidance of treatment, your kindness & your caring!!

Aug 2017

•

Verified SHC Patient

My total experience with Dr. Kwo, Rachel PA, nurses was very professional, friendly and reassuring. 1. Extremely.

Jul 2017

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Paul Kwo

Hepatologist, Transplant hepatologist, Gastroenterologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Liver Transplant Clinic in Pleasanton Pleasanton, CA

Liver Transplant Clinic in Pleasanton

Advanced Endoscopy in Palo Alto Stanford, CA

Advanced Endoscopy in Palo Alto

Hereditary Hemorrhagic Telangiectasia Center of Excellence Stanford, CA

Hereditary Hemorrhagic Telangiectasia Center of Excellence

Stanford Health Care Tri-Valley Pleasanton, CA

Stanford Health Care Tri-Valley

Liver (Hepatology) Clinic in Fremont Fremont, CA

Liver (Hepatology) Clinic in Fremont

Liver (Hepatology) Clinic in Redwood City Redwood City, CA

Liver (Hepatology) Clinic in Redwood City

Digestive Health Center in Redwood City Redwood City, CA

Digestive Health Center in Redwood City

Liver (Hepatology) Clinic in Fresno Fresno, CA

Liver (Hepatology) Clinic in Fresno

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(199 reviews)

Referring Physicians

PHYSICIAN HELPLINE